Sign in

    Justin Wang

    Research Analyst at Morgan Stanley

    Justin Wang is an Equity Research Associate at Morgan Stanley in New York, leveraging over five years of experience in financial services, including prior roles in banking and management consulting. Specializing in equity research, he has contributed to coverage across diverse sectors by supporting senior analysts with in-depth analysis and valuation work, though specific companies covered and quantitative performance metrics are not publicly disclosed. Since joining Morgan Stanley in mid-2022, he has progressed through increasingly responsible roles, following analyst positions at other firms and building on his academic background with both Bachelor's and Master's degrees from the University of Oxford. Wang holds relevant industry experience, but there is no public record confirming FINRA securities licenses or notable external analyst rankings as of August 2025.

    Justin Wang's questions to Sight Sciences (SGHT) leadership

    Justin Wang's questions to Sight Sciences (SGHT) leadership • Q2 2025

    Question

    Justin Wang from Morgan Stanley requested more detail on payer conversations for TearCare, including their reaction to the 24-month SAHARA data and the cost-utility analysis, as well as the potential target reimbursement level.

    Answer

    CFO Ali Bauerlein characterized payer discussions as positive, with high respect for the company's clinical and health economic data, although the final payment rate is still uncertain. CEO Paul Badawi emphasized that the SAHARA trial was specifically designed for payers, demonstrating superiority over the standard of care and long-term durability, which he believes provides a compelling case for coverage.

    Ask Fintool Equity Research AI

    Justin Wang's questions to STERIS (STE) leadership

    Justin Wang's questions to STERIS (STE) leadership • Q1 2026

    Question

    Justin Wang of Morgan Stanley asked why STERIS's ethylene oxide (EO) facilities were not granted regulatory relief from NESHAP compliance and how this development affects the competitive environment.

    Answer

    Daniel Carestio, President & CEO, stated that STERIS did not apply for the two-year extension because it is not needed. He explained that the company has been proactively upgrading its facilities for four years and is confident in its ability to meet compliance deadlines. He views the relief for competitors as not materially impacting the competitive landscape.

    Ask Fintool Equity Research AI

    Justin Wang's questions to TransMedics Group (TMDX) leadership

    Justin Wang's questions to TransMedics Group (TMDX) leadership • Q2 2025

    Question

    Justin Wang, on for Patrick, asked for early surgeon feedback on the NOP Access platform and how it integrates with the broader NOP ecosystem.

    Answer

    CEO Waleed Hassanein described early user feedback on NOP Access as "off the chart." He clarified that NOP Access is the customer-facing portal of a single, seamless digital ecosystem that includes the NOP Connect back-end and integrated logistics and mapping functions.

    Ask Fintool Equity Research AI